MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.940
+0.070
+1.81%
Pre Market: 3.960 +0.02 +0.51% 09:28 05/06 EDT
OPEN
3.930
PREV CLOSE
3.870
HIGH
4.060
LOW
3.850
VOLUME
53
TURNOVER
--
52 WEEK HIGH
13.50
52 WEEK LOW
3.850
MARKET CAP
126.76M
P/E (TTM)
-1.6650
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 1h ago
8-K: CONCERT PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- 0001367920FALSE00013679202021-05-042021-05-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
DJ Concert Pharmaceuticals, Inc. CEO Roger Tung on Q1 2021 Results -- Earnings Call Transcript >CNCE
Dow Jones · 1d ago
Concert Pharmaceuticals Reports First Quarter 2021 Financial Results
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2021. “We are committed to advancing CTP-543, our...
BusinessWire - BZX · 1d ago
Concert Pharma (CNCE) Gets a Buy Rating from Mizuho Securities
SmarterAnalyst · 1d ago
Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 2d ago
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3)
Benzinga · 2d ago
BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.67
reuters.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CNCE. Analyze the recent business situations of Concert Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNCE stock price target is 15.00 with a high estimate of 22.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 145
Institutional Holdings: 26.92M
% Owned: 83.68%
Shares Outstanding: 32.17M
TypeInstitutionsShares
Increased
34
1.46M
New
17
1.77M
Decreased
31
635.24K
Sold Out
8
199.18K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Co-Founder/Independent Director
Richard Aldrich
President/Chief Executive Officer/Co-Founder/Director
Roger Tung
Chief Financial Officer/Chief Accounting Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Other
James Cassella
Other
James Cassella,
Secretary
Jeffrey Munsie
Independent Director
Thomas Auchincloss
Independent Director
Ronald Barrett
Independent Director
Jesper Hoiland
Independent Director
Peter Hutt
Independent Director
Wilfred Jaeger
Independent Director
Christine van Heek
No Data
  • All
  • Financials
  • Insiders
More
About CNCE
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.